Vital Signs - Stem Cell Therapy in Ischemic Stroke Recovery

Additional Clinical Trials Critical to Building on Early Promise

USD 450

* Required Fields

USD 450

PAY BY INVOICE

Be the first to review this product

As indicated by the World Health Organization, stroke is the second-leading cause of death for people over the age of 60 and is the fifth-leading cause of death for those between the ages of 15 and 59. The incidence of stroke is expected to increase by 25% over the next 20 years. Over 40% of ischemic stroke victims have permanent symptoms and only 10% fully recover. Neural stem cells from the brain are capable of dividing, multiplying, and differentiating into different types of brain cells and, thus, may be very useful for the regeneration of brain tissue damaged by ischemic stroke. Although many early human studies indicate a significant improvement of neurological, neuromuscular, and immunological functions, additional clinical trials, either planned or currently underway, will be invaluable as we move forward to elucidate the beneficial nature of stem cell therapy for ischemic stroke.

Table of Contents

Vital Signs - Stem Cell Therapy in Ischemic Stroke RecoveryVital Signs - February 2016February 2016 Issue




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.